This segment focuses on developing XPro1595, a novel immunotherapy targeting neuroinflammation in Alzheimer's disease. Research and development efforts are directed towards understanding the role of soluble TNF (sTNF) in driving neuroinflammation and cognitive decline. XPro1595 is designed to selectively neutralize sTNF without affecting transmembrane TNF, which is crucial for immune function. Clinical trials, such as the Phase 2 MINDFuL trial, aim to demonstrate the efficacy of XPro1595 in reducing neuroinflammation and improving cognitive outcomes in early Alzheimer's patients. The segment's market positioning is centered on providing a targeted approach to address the underlying pathology of Alzheimer's disease, offering a potential alternative to amyloid-based therapies. Future opportunities include expanding clinical trials to larger patient populations and exploring combination therapies to enhance treatment efficacy. Regulatory and clinical aspects involve navigating the FDA approval process and demonstrating long-term safety and efficacy.

The Immuno-Oncology segment is dedicated to developing immunotherapies that harness the patient's innate immune system to fight cancer. Key programs include INKmune, a Natural Killer (NK) cell-based therapy, and INB03, an immunotherapy targeting myeloid-derived suppressor cells (MDSCs). Research and development activities focus on enhancing the cytotoxic activity of NK cells and modulating the tumor microenvironment to promote anti-tumor immunity. INKmune is being evaluated in clinical trials for relapse refractory ovarian carcinoma and high-risk myelodysplastic syndrome. INB03 is designed to deplete MDSCs, which suppress immune responses in cancer patients. The segment's market positioning is focused on providing novel approaches to overcome immune resistance in cancer and improve patient outcomes. Future opportunities include expanding the pipeline with new immunotherapeutic agents and exploring combination therapies with checkpoint inhibitors and other cancer treatments. Collaborations with research institutions and universities are crucial for advancing scientific understanding and accelerating drug development.

This segment focuses on the development and application of the CORDStrom platform, an innovative mesenchymal stromal cell (MSC) therapy. Research and development efforts are directed towards optimizing the manufacturing process and enhancing the therapeutic potential of MSCs. The CORDStrom platform aims to leverage the regenerative and immunomodulatory properties of MSCs to treat various diseases. Clinical trials are planned to evaluate the safety and efficacy of CORDStrom in specific indications. The segment's market positioning is centered on providing a scalable and cost-effective MSC therapy for a wide range of applications. Future opportunities include expanding the platform to address new therapeutic areas and exploring combination therapies with other regenerative medicine approaches. Regulatory and clinical aspects involve navigating the FDA approval process and demonstrating long-term safety and efficacy. Partnerships with cell and gene therapy catapults are crucial for scaling up manufacturing and achieving commercial readiness.